- Home
- ERNA vs CTSO Comparison
ERNA vs CTSO Comparison
Compare ERNA & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERNA
- CTSO
- Stock Information
- Founded
- ERNA 2018
- CTSO 1997
- Country
- ERNA United States
- CTSO United States
- Employees
- ERNA N/A
- CTSO N/A
- Industry
- ERNA Biotechnology: Pharmaceutical Preparations
- CTSO Medical/Dental Instruments
- Sector
- ERNA Health Care
- CTSO Health Care
- Exchange
- ERNA Nasdaq
- CTSO Nasdaq
- Market Cap
- ERNA 56.4M
- CTSO 51.6M
- IPO Year
- ERNA N/A
- CTSO N/A
- Fundamental
- Price
- ERNA $0.42
- CTSO $1.03
- Analyst Decision
- ERNA
- CTSO Strong Buy
- Analyst Count
- ERNA 0
- CTSO 3
- Target Price
- ERNA N/A
- CTSO $4.67
- AVG Volume (30 Days)
- ERNA 30.7M
- CTSO 538.8K
- Earning Date
- ERNA 03-13-2025
- CTSO 03-06-2025
- Dividend Yield
- ERNA N/A
- CTSO N/A
- EPS Growth
- ERNA N/A
- CTSO N/A
- EPS
- ERNA N/A
- CTSO N/A
- Revenue
- ERNA $598,000.00
- CTSO $37,739,531.00
- Revenue This Year
- ERNA N/A
- CTSO $9.20
- Revenue Next Year
- ERNA N/A
- CTSO $11.64
- P/E Ratio
- ERNA N/A
- CTSO N/A
- Revenue Growth
- ERNA 1072.55
- CTSO 1.80
- 52 Week Low
- ERNA $0.22
- CTSO $0.70
- 52 Week High
- ERNA $2.63
- CTSO $1.59
- Technical
- Relative Strength Index (RSI)
- ERNA 54.72
- CTSO 55.82
- Support Level
- ERNA $0.38
- CTSO $1.00
- Resistance Level
- ERNA $0.96
- CTSO $1.14
- Average True Range (ATR)
- ERNA 0.10
- CTSO 0.09
- MACD
- ERNA 0.03
- CTSO 0.01
- Stochastic Oscillator
- ERNA 24.25
- CTSO 64.40
About ERNA Eterna Therapeutics Inc.
Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.